Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Consensus Price Target from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $41.25.

A number of analysts have recently issued reports on the company. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target on the stock.

Oruka Therapeutics Trading Up 0.7 %

Shares of NASDAQ:ORKA opened at $25.00 on Wednesday. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.